Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed or refractory systemic ALCL who have previously received front line chemotherapy.~* Documented anaplastic lymphoma kinase (ALK) status.~* Histologically-confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.~* Fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.~* Received any previous autologous stem cell transplant at least 12 weeks (3 months) prior.~* At US sites, patients greater than or equal to 12 years of age may be enrolled. At non-US sites, patients must be greater than or equal to 18 years of age.~Exclusion Criteria:~* Previous treatment with brentuximab vedotin.~* Previously received an allogeneic transplant.~* Patients with current diagnosis of primary cutaneous ALCL (patients who have transformed to systemic ALCL are eligible).~* Known cerebral/meningeal disease.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).